Latest news

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Alexandre DIAS (IMATHERA, CGFL) obtained funding through the young researcher programm of ANR of €324,000 over 3 years (2024-2027). This project entitled “Improved imaging and therapy of HER2-low breast cancer” (EITHER2BC) aims at developing theranostic probes (combining properties for diagnosis and therapy) targeting HER2, in a HER2-low context, could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of these patients. This project will be driven in collaboration with ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the INCA of €130,000 over 3 years (2024-2027) as partner of a global INCA project entitled “Development of bimodal antibodies targeting colorectal and pancreatic tumors for fluorescenceguided surgery application”. This project is led by Dr Catherine Paul (École Pratique des Hautes Études – Université PSL) and in collaboration with the ICMUB (Dr Goze Christine) and Besançon University Hospital (Dr Doussot Alexandre).

​

Probes developed in this prject will be tested for FGS in various preclinical models mimicking human pathology, such as orthotopic models of colon and pancreatic cancers, but also models mimicking the formation of liver metastases or peritoneal carcinomatosis. The expected results of this project are fine visualisation of tumours before surgery (SPECT imaging) and more accurate detection by fluorescence, enabling the extent of resection to be minimised. Finally, it will be possible to detect the absence of recurrence using this compound a few weeks after surgery (SPECT).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Drs Alexandre COCHET and Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the FEDER of 3.6 M€ over 5 years (2023-2028). This project entitled “moleCular radiOtherapy for Metastatic ColorEcTal and Gastric cancErs” (COMETE) aims at developing theranostic probes (for RIT and associated companion diagnostics) in colorectal and gastric cancers that could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of patients.

This project will be driven by Oncodesign Precision Medicine (OPM, Dijon) with a third parter, ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) was present at the “5ème Journées Scientifiques du GDR Agents d’Imagerie Moléculaire (GDR AIM)” in Paris. Romain Fontaine-Tuffery (ICMUB – UMR CNRS 6302/CGFL) presented his research work as part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) on the synthesis of fluorinated metal porphyrin platforms for PET imaging and photodynamic therapy. This work is under the direction of Dr Bertrand Collin (CGFL/ICMUB) and Dr Richard Decreau (Associate Professor, ICMUB – UMR CNRS 6302).

IMATHERa (CGFL, Dr Bertand Collin, ICMUB – UMR CNRS 6302) was present at the “Journées de recherche respiratoires (J2R)” in Tours. Dr Alexandre Dias (CGFL) presented his research work as part of the HYMAGE-IPF project (ANR-20-CE17-0005) on the development of a theranostic strategy targeting Gp96 in pulmonary fibrosis. This work, under the direction of Dr Pierre-Simon Bellaye (CGFL), was carried out in collaboration with Pr Philippe Bonniaud’s (CHU de Dijon – INSERM U1231, HSP-pathies) team led by Dr Carmen Garrido (INSERM U1231, HSP-pathies).

IMATHERa (CGFL) was present at the European Congress of Nuclear Medicine (EANM) in Vienna. Drs Alan Courteau and Bertrand Collin (CGFL / ICMUB – UMR CNRS 6302) presented their research work part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) program on preclinical multi-animal PET/MRI imaging and preclinical theranostic PET imaging of CD30-positive cancers with [Zr89]Zr-DFO-Brentuximab vedotin, respectively.

IMATHERa (CGFL) was present at the World Molecular Imaging Congress (WMIC) in Prague. Dr Alexandre Dias (CGFL) and Dr Bertrand Collin (CGFL / ICMUB – UMR CNRS 6302) presented their research work part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) program on:

– Preclinical theranostic PET imaging in CD30-positive cancers with [Zr89]Zr-DFO-Brentuximab vedotin.

– SPIOs development for theranostic purposes in glioblastoma.

On this occasion, the title of Scientific Ambassador for France was awarded to Dr Alexandre Dias for his work on the use of SPIOs in the treatment of glioblastoma, in collaboration with the Dijon-based company SON SAS.

A new review article, co-authored by Drs Jame Frenay and Pierre-Simon Bellaye (Supervisor: Dr Alexandre Dias), has just been published by IMATHERa (CGFL – Dr B. Collin, ICMUB UMR CNRS 6302). This literature review highlights the fact that IL-1RAP, a receptor involved in the inflammatory response, is now considered as a promising therapeutic target in several hematological and solid cancers: see publication.

A new review article, co-authored by Drs Alexandre Dias and Alan Courteau, has just been published by IMATHERa (CGFL – Dr B. Collin, ICMUB UMR CNRS 6302).

This literature review highlights the theranostic potential of innovative superparamagnetic nanoparticles for cancer immunotherapy via magnetic hyperthermia and targeting of M2 macrophages: https://www.mdpi.com/1999-4923/14/11/2388.